
Lonza makes change at the top
pharmafile | April 30, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Lonza, funk
Swiss pharma supplier firm Lonza has confirmed a leadership change as its chief operating officer (COO) leaves.
Marc Funk has been appointed COO of the Pharma&Biotech segment as Stephan Kutzer has decided to depart from the company.
As of 1 July Funk will take on the full leadership role for its Pharma&Biotech unit from Kutzer, who will ensure that the handover is completed and is to conduct additional transitional activities.
Lonza’s chief executive Richard Ridinger says: “Marc has been the Group’s chief legal officer and board secretary since 2009 and a member of the EC since 2012. He has already successfully managed operational and commercial projects in the Pharma&Biotech network and has been responsible for Global Quality in Pharma&Biotech for more than a year.
“Also he has broad experience in this field as he was formerly co-founder of a biotech research company and has had a strong commercial focus in other parts of his career. I am confident he’ll be able to steer that segment through this critical growth phase and into the future.”
Related Content

Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …

Lonza to acquire Synaffix to strengthen ADC development
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …

Moderna submits BLA with FDA for COVID vaccine
Moderna has initiated the rolling submission process with the FDA for a Biologics License Application …






